Theranexus Stock

Equities

ALTHX

FR0013286259

Biotechnology & Medical Research

Real-time Euronext Paris 05:27:41 2024-04-25 am EDT 5-day change 1st Jan Change
1.115 EUR -0.45% Intraday chart for Theranexus +5.69% -0.45%
Sales 2023 * - Sales 2024 * - Capitalization 8.69M 8.11M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * -
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * -
P/E ratio 2023 *
-1.11 x
P/E ratio 2024 *
-
Employees 19
Yield 2023 *
-
Yield 2024 *
-
Free-Float 78.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.45%
1 week+5.69%
Current month-3.21%
1 month+2.67%
3 months+13.89%
6 months-2.19%
Current year-0.45%
More quotes
1 week
0.99
Extreme 0.99
1.28
1 month
0.99
Extreme 0.99
1.30
Current year
0.63
Extreme 0.63
1.35
1 year
0.63
Extreme 0.63
3.18
3 years
0.63
Extreme 0.63
14.36
5 years
0.63
Extreme 0.63
23.60
10 years
0.63
Extreme 0.63
23.60
More quotes
Managers TitleAgeSince
Chief Executive Officer - 13-03-18
Founder - 13-03-18
Director of Finance/CFO - 16-12-31
Members of the board TitleAgeSince
Director/Board Member 63 18-12-12
Director/Board Member 50 17-09-25
Founder - 13-03-18
More insiders
Date Price Change Volume
24-04-25 1.115 -0.45% 8 833
24-04-24 1.12 -0.88% 19,374
24-04-23 1.13 +8.13% 61,490
24-04-22 1.045 -0.48% 7,188
24-04-19 1.05 -0.47% 141,763

Real-time Euronext Paris, April 25, 2024 at 05:27 am EDT

More quotes
Theranexus is an innovative biopharmaceutical company that emerged from the French Atomic Energy Commission (CEA) and specializes in the treatment of neurological diseases and pioneer in the development of drug candidates targeting both neurons and glial cells. Theranexus has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.12 EUR
Average target price
4 EUR
Spread / Average Target
+257.14%
Consensus

Annual profits - Rate of surprise